ArticleCell communication and signaling : CCS2026
Reprogramming the epigenetic profile improves the B regulatory cell function of patients with recurrent pregnancy loss.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunoglobulins in recurrent pregnancy loss: Emerging biomarkers and therapeutic targets.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNearly half of patients with recurrent pregnancy loss (RPL) link to disrupted maternal immune tolerance. IL-10-production regulatory B cells (Bregs) are functionally impaired in RPL, but the underlying mechanisms remain unclear. This study aimed to identify these mechanisms and test suberoylanilide hydroxamic acid (SAHA) as a potential therapy.
methodsPeripheral Bregs were isolated from 30 RPL patients and 30 healthy controls (HCs). Epigenetic assays (chromatin immunoprecipitation for DNMT1 occupancy, methylation profiling of the IL10 promoter), ubiquitination analyses (focusing on K48-linked polyubiquitin chains), and functional co-cultures with CD3/CD28-activated effector T cells (Teffs) were performed. SAHA (0.5-5 μM) was tested after validating non-toxicity via cell viability assays.
resultsCompared to HCs, RPL Bregs showed significantly elevated IL10 promoter methylation (HC: 22 ± 5% vs. RPL: 48 ± 8%; p < 0.0001) and overexpression of DNA methyltransferase 1 (DNMT1), which correlated with reduced IL-10 secretion (HC: 325 ± 45 pg/mL vs. RPL: 180 ± 30 pg/mL; p < 0.001) and impaired Teff suppression (suppressive index: HC: 0.52 ± 0.08 vs. RPL: 0.21 ± 0.06; p < 0.001). DNMT1 accumulation in RPL Bregs was driven by reduced binding to the E3 ubiquitin ligase TRIM28, leading to diminished K48-linked polyubiquitination (a signal for proteasomal degradation). Treatment with SAHA restored TRIM28 expression, enhanced DNMT1 ubiquitination and degradation, reversed IL10 promoter hypermethylation, and rescued IL-10 secretion and Breg-mediated Teff suppression. These effects were abolished by TRIM28 siRNA, confirming TRIM28 dependence.
conclusionTRIM28 deficiency disrupts DNMT1 degradation, leading to DNMT1-mediated IL10 silencing and Breg dysfunction in RPL. SAHA targets the TRIM28-DNMT1-IL10 axis to restore immune tolerance, representing a precision therapy for immune-mediated RPL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.